Non-Hodgkins Lymphoma

Oncology
8
Pipeline Programs
6
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
480%
ADC
120%
+ 3 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
2 programs
2
IfosfamidePhase 21 trial
RituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00193505Completed40Est. Aug 2005
NCT00193440Completed40Est. Jan 2009
TG Therapeutics
TG TherapeuticsNEW YORK, NY
2 programs
1
1
UblituximabPhase 1/2Monoclonal Antibody1 trial
UblituximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT01744912Terminated10Est. Feb 2014
NCT01647971Completed39Est. May 2015
Bayer
BayerLEVERKUSEN, Germany
1 program
1
RituximabPhase 1/2Monoclonal Antibody2 trials
Active Trials
NCT00807196Unknown20Est. Dec 2012
NCT00689169Completed75Est. Jan 2014
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
Aurora kinase inhibitor AT9283Phase 11 trial
Active Trials
NCT00443976CompletedEst. Jan 2012
Novartis
NovartisBASEL, Switzerland
1 program
1
JBH492Phase 11 trial
Active Trials
NCT04240704Terminated25Est. Sep 2024
Genentech
GenentechCA - Oceanside
1 program
1
Polatuzumab VedotinPhase 1ADC1 trial
Active Trials
NCT01290549Completed95Est. Nov 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerRituximab
BiogenIfosfamide
BiogenRituximab
TG TherapeuticsUblituximab
BayerRituximab
NovartisJBH492
TG TherapeuticsUblituximab
GenentechPolatuzumab Vedotin
Astex PharmaceuticalsAurora kinase inhibitor AT9283

Clinical Trials (9)

Total enrollment: 344 patients across 9 trials

NCT00689169BayerRituximab

Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

Start: Aug 2007Est. completion: Jan 201475 patients
Phase 2Completed
NCT00193505BiogenIfosfamide

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Start: Oct 2003Est. completion: Aug 200540 patients
Phase 2Completed
NCT00193440BiogenRituximab

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Start: Apr 2002Est. completion: Jan 200940 patients
Phase 2Completed
NCT01647971TG TherapeuticsUblituximab

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start: Jul 2012Est. completion: May 201539 patients
Phase 1/2Completed
NCT00807196BayerRituximab

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Start: Sep 2008Est. completion: Dec 201220 patients
Phase 1/2Unknown
NCT04240704NovartisJBH492

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Start: Sep 2020Est. completion: Sep 202425 patients
Phase 1Terminated
NCT01744912TG TherapeuticsUblituximab

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Start: Nov 2012Est. completion: Feb 201410 patients
Phase 1Terminated
NCT01290549GenentechPolatuzumab Vedotin

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Start: Mar 2011Est. completion: Nov 201495 patients
Phase 1Completed
NCT00443976Astex PharmaceuticalsAurora kinase inhibitor AT9283

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Start: Jan 2007Est. completion: Jan 2012
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
18m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Monoclonal Antibody is the dominant modality (80% of programs)
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)